MedTrace Logo

A Phase I Study of JSKN021 in Advanced Solid Tumors

NCT07617727 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2026-07-30

No results posted yet for this study

Summary

This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK) profiles, and the preliminary antitumor activity of JSKN021 in advanced malignant solid tumors.

Conditions

  • Advanced Malignant Solid Tumors

Interventions

DRUG

JSKN021

JSKN021 administered intravenously at selected dose levels according to protocol

Sponsors & Collaborators

  • Jiangsu Alphamab Biopharmaceuticals Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-02
Primary Completion
2028-10-31
Completion
2029-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07617727 on ClinicalTrials.gov